PT - JOURNAL ARTICLE AU - Erik Volz AU - Swapnil Mishra AU - Meera Chand AU - Jeffrey C. Barrett AU - Robert Johnson AU - Lily Geidelberg AU - Wes R Hinsley AU - Daniel J Laydon AU - Gavin Dabrera AU - Áine O’Toole AU - Roberto Amato AU - Manon Ragonnet-Cronin AU - Ian Harrison AU - Ben Jackson AU - Cristina V. Ariani AU - Olivia Boyd AU - Nicholas J Loman AU - John T McCrone AU - Sónia Gonçalves AU - David Jorgensen AU - Richard Myers AU - Verity Hill AU - David K. Jackson AU - Katy Gaythorpe AU - Natalie Groves AU - John Sillitoe AU - Dominic P. Kwiatkowski AU - The COVID-19 Genomics UK (COG-UK) consortium AU - Seth Flaxman AU - Oliver Ratmann AU - Samir Bhatt AU - Susan Hopkins AU - Axel Gandy AU - Andrew Rambaut AU - Neil M Ferguson TI - Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data AID - 10.1101/2020.12.30.20249034 DP - 2021 Jan 01 TA - medRxiv PG - 2020.12.30.20249034 4099 - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20249034.1.short 4100 - http://medrxiv.org/content/early/2021/01/04/2020.12.30.20249034.1.full AB - The SARS-CoV-2 lineage B.1.1.7, now designated Variant of Concern 202012/01 (VOC) by Public Health England, originated in the UK in late Summer to early Autumn 2020. We examine epidemiological evidence for this VOC having a transmission advantage from several perspectives. First, whole genome sequence data collected from community-based diagnostic testing provides an indication of changing prevalence of different genetic variants through time. Phylodynamic modelling additionally indicates that genetic diversity of this lineage has changed in a manner consistent with exponential growth. Second, we find that changes in VOC frequency inferred from genetic data correspond closely to changes inferred by S-gene target failures (SGTF) in community-based diagnostic PCR testing. Third, we examine growth trends in SGTF and non-SGTF case numbers at local area level across England, and show that the VOC has higher transmissibility than non-VOC lineages, even if the VOC has a different latent period or generation time. Available SGTF data indicate a shift in the age composition of reported cases, with a larger share of under 20 year olds among reported VOC than non-VOC cases. Fourth, we assess the association of VOC frequency with independent estimates of the overall SARS-CoV-2 reproduction number through time. Finally, we fit a semi-mechanistic model directly to local VOC and non-VOC case incidence to estimate the reproduction numbers over time for each. There is a consensus among all analyses that the VOC has a substantial transmission advantage, with the estimated difference in reproduction numbers between VOC and non-VOC ranging between 0.4 and 0.7, and the ratio of reproduction numbers varying between 1.4 and 1.8. We note that these estimates of transmission advantage apply to a period where high levels of social distancing were in place in England; extrapolation to other transmission contexts therefore requires caution.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCOG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. The Imperial College COVID-19 Research Fund, UKRI (MR/V038109/1), The Academy of Medical Sciences (SBF004/1080), Bill & Melinda Gates Foundation (OPP1197730, OPP1175094), the European Commission (CoroNAb 101003653), the NIHR BRC Imperial College NHS Trust Infection and COVID themes (RDA02), Amazon AWS and Microsoft AI for Health, the EPSRC, The Medical Research Council (MR/R015600/1), the NIHR Health Protection Research Unit for Modelling and Health Economics, NIHR VEEPD project funding. Wellcome core funding to the Wellcome Sanger Institute (206194).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll aggregated data to reproduce analysis will be provided in the url below. https://github.com/mrc-ide/covid19-variant-N501Y